For any investor related questions, please contact:

Investor Relations
626-334-5310

investorrelations@viralgenetics.com




Home | About Us | Our Team | Advisory Board | Discovery
Our Vision | Immune-Based Therapies | TNP | Development | VGV-1
History | Product Timeline | Clinical Trials
Press Releases | Media Kits | Media Inquiries | News Subscription Service
Investor Contacts | Email Alerts | Contact Us | SEC Filings
Glossary | Stock Information | Corporate Governance & Board of Directors
University of Colorado License | Careers